Oridonin Attenuates Synaptic Loss and Cognitive Deficits in an Aβ₁₋₄₂-Induced Mouse Model of Alzheimer’s Disease

Sulei Wang¹*, Linjie Yu²*, Hui Yang¹, Chaosheng Li¹, Zhen Hui¹, Yun Xu¹,²,³,⁴,⁵*, Xiaolei Zhu²*

¹ Department of Neurology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, PR China, ² Department of Neurology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, PR China, ³ Jiangsu Stroke Research Collaborative Group, Nanjing, PR China, ⁴ Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, PR China, ⁵ Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, PR China

* These authors contributed equally to this work.

Abstract

Synaptic loss induced by beta-amyloid (Aβ) plays a critical role in the pathophysiology of Alzheimer’s disease (AD), but the mechanisms underlying this process remain unknown. In this study, we found that oridonin (Ori) rescued synaptic loss induced by Aβ₁₋₄₂ in vivo and in vitro and attenuated the alterations in dendritic structure and spine density observed in the hippocampus of AD mice. In addition, Ori increased the expression of PSD-95 and synaptophysin and promoted mitochondrial activity in the synaptosomes of AD mice. Ori also activated the BDNF/TrkB/CREB signaling pathway in the hippocampus of AD mice. Furthermore, in the Morris water maze test, Ori reduced latency and searching distance and increased the number of platform crosses in AD mice. These data suggest that Ori might prevent synaptic loss and improve behavioral symptoms in Aβ₁₋₄₂-induced AD mice.

Introduction

Alzheimer’s disease (AD) is the most common cause of dementia in the elderly and is a prevalent neurodegenerative disease characterized by neuronal loss, extracellular senile plaques and intracellular neurofibrillary tangles. In 2015, an estimated 5.3 million people have AD in United States, and AD makes the sixth leading cause of death[1]. Although the underlying mechanisms of AD have not been fully elucidated, converging lines of evidence indicate that the accumulation of beta-amyloid (Aβ) is the key event in AD pathology. Aβ peptides are produced from the consecutive cleavage of β-amyloid precursor protein (APP) by β-secretase and γ-secretase, and Aβ₁₋₄₂ is considered as the major neurotoxic Aβ species in the brain[2,3]. Genetic evidence has established the causative role of Aβ generation in AD pathogenesis, and this amyloidogenic processing of APP might be linked to essential cellular processes uniquely disrupted in AD brains[4,5]. The deposition of Aβ affects the morphology and function of synapses by disrupting the synaptic signaling pathways and destroys dendritic spines, which leads...
to deficits in memory and behavior[6]. In addition, brain tissues from AD patients show a marked loss of synapses, which could underlie the observed cognitive decline[7]. Emerging evidence also suggests that protecting synapses could attenuate the observed memory deficits in animal models of AD[8,9], which indicates that new approaches that target synapses could provide disease-modifying therapeutics.

Synaptic dysfunction in AD has been extensively studied, and the results suggest a central role for the synapse in AD pathogenesis. However, the exact mechanisms by which Aβ specifically targets synapses remain largely unknown. Brain-derived neurotrophic factor (BDNF), a member of neurotrophin family, plays a critical role in synaptic regulation and is thought to ensure synaptic growth, promote synaptic transmission and enhance synaptic plasticity[10]. A reduction in BDNF expression has been found in the hippocampus of AD mice[11]. In addition, Aβ significantly decreases the levels of BDNF in dendritic cells derived from AD patients[12]. The biological function of BDNF is regulated by its high-affinity receptor, tropomyosin-related kinase B (TrkB), which is known to be coupled to the activation of the phosphatidylinositol 3-kinase/Akt, phospholipase C-γ (PLC-γ) and Ras/ERK pathways[13]. Aβ decreases TrkB expression in the hippocampal dentate gyrus of Aβ-injected rats[14], and activating TrkB protects neurons against Aβ toxicity[15]. cAMP response element-binding protein (CREB), a downstream target of this pathway, is strongly related to the maintenance and activity of synapses and the formation of memories[16–18]. Taken together, these results support the hypothesis that the BDNF/TrkB/CREB pathway is involved in the pathological processes of AD.

Oridonin (Ori), isolated from the traditional Chinese herb Rabdosia rubescens, is an active diterpenoid which is a trepenoid with the C20 skeleton, Ori has diverse pharmaceutical and biological factions and has already been used in clinical practice. We have previously reported that Ori suppresses Aβ-induced neuroinflammation by inhibiting the NF-κB pathway[19]. Thus, in this study, we show the effects of Ori on Aβ1–42-induced synaptic loss and investigate the molecular mechanisms involved in the protection of synapses.

**Materials and Methods**

**Reagents and antibodies**

Human Aβ1–42 was purchased from EMD Millipore Corporation (Billerica, MA, USA). Ori was obtained from Chengdu Must Bio-Technology Company (Sichuan, China). Neurobasal media and B27 were bought from Life Technologies Corporation. MAP-2 antibody was purchased from Abcam (Cambridge, MA, USA). COX-2 antibody was bought from Santa Cruz Biotechnology (Santa Cruz, USA). PSD-95 antibody, synaptophysin antibody and CREB antibody were obtained from CST (Cell Signaling Technology, USA). 4', 6'-diamidino-2-phenylindole (DAPI), VDAC1, BDNF, p-TrkB, TrkB, p-CREB and β-actin antibodies were purchased from Bioworld Technology (Bioworld, USA). Lamin B1 antibody and HRP-conjugated secondary antibodies were also obtained from Bioworld.

**Animals**

Experiments were conducted using male C57BL/6 (B6) mice weighing 20–26 g. This study was reviewed and approved by the Animal Care Committee of Nanjing University. We made every effort to minimize the number of mice used and their suffering, and no mice died through the experiment. Mice were housed in specific pathogen free (SPF) cages under standard laboratory conditions including 21±1°C temperature, 40–55% relative humidity and 12-h light/dark cycle with free access to water and food. All mice in the study were sacrificed after the treatment. The mice were anesthetized with sodium pentobarbital (50 mg/kg) and decapitated, and brain...
tissues were removed for the western blot and synaptosomes study. In the immunostaining study, the mice were anesthetized and perfused intracardially with 0.9% saline followed by 4% paraformaldehyde. The brains were removed and sequentially post-fixed in 15% and 25% sucrose solutions. The experiments were performed in a double-blinded manner.

**AD mouse model and treatment with Ori**

$\mathrm{A_\beta}_{1-42}$ was prepared with 1% NH$_3$xH$_2$O at a concentration of 1 mg/ml and incubated at 37°C for 5 days to allow for oligomerization as described previously[20]. Ori was dissolved in DMSO at a concentration of 20 mg/ml and diluted to the desired concentration in saline as described previously[19]. The i.c.v microinjections of $\mathrm{A_\beta}_{1-42}$ (4 μg) into the bilateral hippocampus of male C57BL/6 (B6) mice were given via infusion cannulae as previously described[21]. After injecting $\mathrm{A_\beta}_{1-42}$ for 7 days, Ori was injected intraperitoneally once a day for 15 days. Ori (10 mg/kg/day, i.p. for 15 days) attenuated memory deficits in $\mathrm{A_\beta}_{1-42}$ induced AD mice, but it did not exert the protective effects at higher doses (20–50 mg/kg/day)[19]. Thus, the dose of 10 mg/kg/day intraperitoneally injected for 15 days was used in this study. Mice were divided into the following groups: control mice (sham-operated) that received saline; control mice (sham-operated) that received Ori (10 mg/kg/day, i.p. for 15 days); $\mathrm{A_\beta}_{1-42}$-induced AD mice that received saline; and $\mathrm{A_\beta}_{1-42}$-induced AD mice that received Ori (10 mg/kg/day, i.p. for 15 days). At the end of the treatment, mice were behaviorally tested and sacrificed for the following experiments.

**Cell culture and stimulation**

Primary cortical neurons were derived from the brains of E15-17 C57BL/6 (B6) mouse embryos as previously described[22]. Briefly, the cerebral cortex was isolated, trypsinized in 0.25% trypsin at 37°C for 10 min and seeded onto 24-well poly-D-lysine-coated plates with cover slips at a density of $5 \times 10^5$ cells/ml. Cells were cultured in neurobasal media supplemented with B27 and 25 nmol/L glutamine at 37°C in a humidified 5% CO$_2$ incubator. Neurons were maintained in the media for 8 days, and the purity of the primary neurons was more than 95%. Neurons were pre-treated with Ori (10–100 μM) for 1 h and 2 μM $\mathrm{A_\beta}_{1-42}$ for 6 h, and then prepared for the following experiments. Our preliminary data indicated that Ori (40 μM) significantly increased the viability of neurons treated with $\mathrm{A_\beta}_{1-42}$, while the doses of more than 40 μM did not exert the protective effects (data not shown), and the dose of 40 μM was used in this study.

**Western blotting**

Three animals from each group were euthanized and decapitated, and the hippocampus of the mice were removed and sonicated in RIPA buffer (Beyotime Institute of Biotechnology, China) containing phosphatase and protease inhibitor cocktails (Sigma-Aldrich, USA). The total protein was obtained from the supernatant of this extract following 30 min of centrifugation at 12000×rpm, and the protein content was quantified by the BCA protein assay kit (Bioworld, USA). Western blotting was performed as described previously[23]. Samples (30 μg protein) were separated by SDS-PAGE and electrophoretically transferred onto PVDF membranes. Membranes were blocked for 1 h in 5% non-fat milk and incubated overnight with primary antibodies. β-actin was used as a loading control. The incubation with primary antibodies was followed by a 2 h incubation with HRP-conjugated anti-rabbit or anti-mouse secondary antibodies. The protein signals were detected using the chemiluminescence reagents provided with the ECL kit (Bioworld, USA), and Image J software was used to determine the intensity of the blots.
Immunostaining

Immunostaining was performed as described previously[24]. After being anesthetized, mice were perfused intracardially with 0.9% saline followed by 4% paraformaldehyde. The brains were removed and sequentially post-fixed in 15% and 25% sucrose solutions. Subsequently, the brains were cut into 15 μm sections using a cryostat microtome (Leica, Germany). After washing in phosphate buffered saline (PBS) three times for 10 min each and blocking in 3% BSA for 1 h at room temperature, the sections were incubated overnight with an anti-BDNF antibody at 4°C. After washing in PBS three times for 10 min each, the samples were incubated with the secondary antibody for 1 h at 37°C in the dark. Subsequently, the cell nuclei were labeled by DAPI. Images were detected using an OLYMPUS BX51 microscope (Olympus, Japan).

For double immunostaining, cells were washed three times with PBS and then fixed in 4% paraformaldehyde for 30 min at room temperature. Subsequently, cells were blocked with 3% BSA for 60 min. After an overnight incubation with anti-PSD-95 antibody or anti-synaptophysin antibody and MAP-2 antibody at 4°C, the cover slips were washed for 10 min three times and then incubated with goat anti-rabbit and goat anti-mouse antibodies for 1 h at 37°C in the dark. DAPI was used to stain the cell nuclei, and images were acquired using an OLYMPUS BX51 microscope. The immunostaining analysis was performed as described previously[25]. All procedures were conducted in a randomized and blinded manner.

Morris water maze (MWM) test

Cognitive function was evaluated by the Morris water maze as previously described[23]. Briefly, the test involved 5 days of acquisition training with four trials per day. For each trial, each mouse was given 60 s to find a platform that was submerged 2 cm underwater in a circular black pool; if the mouse failed to find the platform within this period, they were manually placed on the platform for 10 s, and the latency was recorded for 60 s. The escape distance, escape latency and swimming speed were analyzed by Any-maze software (Stoelting, USA). On the 6th day, the hidden platform was removed from the water maze, and mice were allowed to swim freely for 60 s; the number of times the mouse crossed the target platform were recorded. The observers were blind to the experimental conditions.

Synaptosomal preparation

To obtain synaptosomes, mice were anesthetized, and their brains were removed, weighed and dounced in a glass Teflon homogenizer in 10 vol (1:10, wt/vol) of Syn-PER synaptic protein extraction reagent (Thermo, Rockford, USA) supplemented with a protease and phosphatase inhibitor cocktail. Following the manufacturer’s instructions, the homogenate was centrifuged at 1200g for 10 min at 4°C, and then the supernatant was centrifuged for a further 20 min at 15000g at 4°C. The supernatant (cytosolic fraction) was removed, and the synaptosome pellets were resuspended in Syn-PER reagent. The protein concentration of synaptosomes was determined by the BCA method.

Synaptosome activity assay

The synaptosome activity assay was performed as described previously[26]. The relative amount of mitochondria was determined by western blot with VDAC1 as a loading control. The mitochondrial activity, an index of the functional status of the synaptosomes, was assessed by the conventional 3-[4, 5-diethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, 2.0 mg of synaptosome protein was prepared, and MTT solution (5 mg/ml in
PBS) was added and incubated at 37°C for 3 h. Subsequently, formazan crystals were dissolved in DMSO, and the absorbance was read at 570 nm by a microplate reader.

**Golgi staining**

The morphology of dendritic spines in the brain was analyzed using a FD Rapid GolgiStain Kit (FD Neurotechnologies, Elliot City, MD, USA) according to the manufacturer’s instructions. Briefly, after being anesthetized, the mouse brains were quickly removed and washed in double distilled water (DDW). Subsequently, the brains were submerged in impregnation solution for 2 weeks at room temperature in the dark. The impregnation solution was replaced on the next day. Samples were removed to solution C for 2 days at room temperature in the dark, sectioned into 200 μm sections by a cryostat microtome and placed onto microscope slides. Sections were washed three times for 10 min each and placed in a mixture composed of solution D, solution E and DDW for 10 min followed by two rinses in DDW for 4 min each. The slides were dehydrated, cleared and coverslipped.

**Analysis of dendritic morphology**

Dendritic morphology was measured by an investigator blind to the experimental conditions using an OLYMPUS BX51 microscope (Olympus, Japan). Golgi-stained brains from 6 mice from each group were subjected to morphological analysis, and 6 neurons from the hippocampus of each brain were selected randomly for analysis. In addition, the spine density was observed under a 100x oil immersion and was expressed as the number of spines per 10 μm of dendrite. The total dendritic length, numbers of branches and spine density were measured by Image J software.

**Statistical analysis**

All data are presented as the means ± SEM and analyzed using SPSS version 13.0 (SPSS, Chicago, IL, USA). For the MWM tasks, group differences in the escape latency, searching distance and swimming speed during the MWM test were analyzed using two-way analysis of variance (ANOVA) with repeated measures followed by Bonferroni multiple comparison test with day and treatment as the sources of variation. All other data were analyzed with a one-way ANOVA followed by Bonferroni’s post hoc. P-values smaller than 0.05 (P<0.05) were considered statistically significant.

**Results**

**Ori increases the expression of PSD-95 and synaptophysin in the hippocampus of AD mice**

Synaptic loss is one of the neuropathological hallmarks of AD, and synaptophysin and PSD-95 are the markers of the pre- and post-synapse, respectively. Compelling evidence has shown that the levels of PSD-95 and synaptophysin are reduced in AD transgenic mouse models [27,28] and in brains from AD patients[29]. In this study, we first tested the expression of PSD-95 and synaptophysin in the hippocampus of AD mice. As shown in Fig 1, the western blot analysis revealed significant reductions of PSD-95 and synaptophysin expression in the hippocampal samples. However, after Ori treatment, the expressions of PSD-95 and synaptophysin were significantly increased compared to the AD group. These data indicated that Ori attenuated the loss of synaptic proteins that was induced by Aβ in vivo.
Ori promotes the expression of PSD-95 and synaptophysin in Aβ1–42 treated neurons

To explore whether Ori could rescue PSD-95 and synaptophysin expression in Aβ1–42-treated neurons, we observed the expression of PSD-95 and synaptophysin by immunostaining. As shown in Fig 2, the levels of PSD-95 (Fig 2A and 2B) and synaptophysin (Fig 2C and 2D) were significantly decreased in the AD group, and this reduction was partially reversed by Ori treatment. Thus, our results indicated that Ori attenuated synaptic loss in vivo and in vitro.

Ori rescues the dendritic morphological changes in the hippocampus of AD mice

The development of dendrites and the number of dendritic spines, which are compromised in AD mice, can both affect synaptic function[30]. Here, we used Golgi staining to examine the effects of Ori on dendritic morphology. As shown in Fig 3A, the total dendritic length and the number of branches did not differ between control and Ori-injected mice. Aβ significantly decreased the total dendritic length compared to control mice, while Ori-treated AD mice had significantly longer dendrites compared to untreated AD mice. Moreover, AD mice showed a reduction in the number of dendritic branches, whereas the number of branches was markedly increased following Ori treatment. To further characterize the differences in dendritic morphology between groups, we examined the density of dendritic spines. The hippocampus of AD mice exhibited a lower density of spines, and this reduction in spine density could be rescued by Ori (Fig 3D).

Ori increases the expression of PSD-95 and synaptophysin and promotes mitochondrial activity in the synaptosomes of AD mice

Synaptosomes, which are isolated synaptic terminals from neurons, can provide material for protein experiments and studies of the maintenance of metabolic activity. We also examined the levels of PSD-95 and synaptophysin in synaptosomes. As shown in Fig 4A and 4B, Ori
Oridonin Attenuates Synaptic Loss and Cognitive Deficits

A

PSD-95

MAP-2

Merge

B

Normalized intensity

Con  Ori  Aβ  Aβ + Ori

C

synaptophysin

MAP-2

Merge

D

Normalized intensity

Con  Ori  Aβ  Aβ + Ori
significantly upregulated the expression of PSD-95 and synaptophysin in the synaptosomes, which was consistent with our results shown in Fig 1. Given that there were no significant differences in the levels of VDAC1 (Fig 4C and 4D), we next measured mitochondrial activity via the MTT assay. As shown in Fig 4E, mitochondrial activity was significantly reduced in synaptosomes from AD mice compared to controls. However, treatment with Ori ameliorated the Aβ-induced reduction in mitochondrial MTT. These data also demonstrated that Ori exerted protective effects on the viability of synapses.

Ori treatment enhances the BDNF/TrkB/CREB signaling pathway in the hippocampus of AD mice

Next, we investigated whether Ori activated the BDNF/TrkB/CREB signaling pathway. As shown in Fig 5, the levels of BDNF, p-TrkB and p-CREB were decreased in the hippocampus of AD mice compared to control mice, and the levels of all three proteins were significantly upregulated after Ori treatment. Our immunostaining also indicated that the reduction in BDNF expression was reversed by Ori (Fig 6). These results showed that the activation of the BDNF/TrkB/CREB signaling pathway might participate in the neuroprotective effects mediated by Ori.

Ori improves cognitive deficits in Aβ1-42-induced AD mice

Finally, to examine whether Ori improved the cognitive deficits induced by Aβ, we measured the therapeutic potential of Ori to reverse AD-induced declines in spatial memory and learning ability by the Morris water maze. The AD group showed a longer escape latency compared to the control group. However, the reduced latency induced by Aβ was ameliorated by the administration of Ori (Fig 7A). The increase in searching distance induced by Aβ was also improved following Ori treatment (Fig 7B). On the 6th day of testing, the hidden platform was removed from the pool, and all groups of mice were allowed to swim for 1 min. The number of platform crosses by Ori-treated mice was dramatically increased compared to AD mice (Fig 7C). Throughout the entire trial, no significant differences in swimming speed were observed across the groups (Fig 7D), suggesting that there were no differences in motivation. The results from the MWM tests indicated that Ori improved the spatial learning and memory disorders in AD mice.

Discussion

Aβ plays a critical role in producing the cognitive dysfunction and other characteristics of AD, including synaptic loss, neuroinflammation, neuronal apoptosis, and neurofibrillary tangles. However, the underlying mechanism for Aβ-mediated synaptic loss is not yet fully understood. In current study, we demonstrated that Ori activated the BDNF/TrkB/CREB signaling pathway, prevented synaptic loss and dysfunction and ameliorated cognitive deficits in Aβ-induced AD mice.

Although the exact cause of AD is poorly understood, the production and deposition of Aβ is widely believed to be involved in its pathogenesis. The essential role of Aβ suggests that
Fig 3. Effects of Ori on the total dendritic length, number of branches and spine density in the hippocampus of AD mice. (A) Representative dendritic images from the hippocampus of mice. Scale bar = 20 μm. (B) Quantitative analysis of the total dendritic length. (C) Quantitative analysis of the number of branches. (D) Representative dendritic spine images from the hippocampus of mice. Scale bar = 10 μm. (E) Quantitative analysis of spine density. Six neurons from each brain were selected for analysis and 6 mice were used from each group. Data are presented as the means ± SEM. *P<0.05, **P<0.01 vs. control; #P<0.05, ##P<0.01 vs. Aβ1–42.

doi:10.1371/journal.pone.0151397.g003
Therapies that target Aβ might be promising for the treatment of AD. Because the major form of amyloid deposition is primarily Aβ1-42[31] and because the levels of Aβ1-42 are thought to be a potential differentiator between AD and non-AD dementias[32], we used the oligomerization of Aβ1-42 in vivo and in vitro. In AD, Aβ-induced synaptic dysfunction and loss is an

---

Fig 4. Ori increases the expression of PSD-95 and synaptophysin and promotes mitochondrial activity in the synaptosomes of AD mice. (A) Western blotting for PSD-95, synaptophysin, COX-2 and Lamin B1 proteins. The absence of the cytosolic protein COX-2 and the nuclear protein Lamin B in the synaptosome pellets confirms the purity of synaptosomes. (B) Quantitative analysis of PSD-95 and synaptophysin expression. The relative expression levels of PSD-95 and synaptophysin were normalized against β-actin and are presented as the ratio of the values of the experimental group to the control group. (C) Western blotting for VDAC1 protein. (D) Quantitative analysis of VDAC1 expression. (E) MTT assay for mitochondrial activity of synaptosomes. n = 5 mice per group and the experiment was performed for three times. Data are presented as the means ± SEM. *P<0.05, **P<0.01 vs. control; #P<0.05, ##P<0.01 vs. Aβ1-42.

doi:10.1371/journal.pone.0151397.g004
important event that is associated with memory deficits, and a reduction of synapses and
decrease in synaptic markers have been widely reported in early and late stages of AD[33–37].
Aβ exerts its synaptotoxicity by binding to synapses, which leads to suppression of long-term
potentiation (LTP), impairments in synaptic plasticity and neuronal dysfunction[38]. In addi-
tion, the Aβ-induced loss of synapse number occurs in a dose-dependent manner[39]. In this
study, PSD-95 and synaptophysin were significantly reduced in Aβ-induced AD mice; how-
ever, this loss was attenuated by Ori treatment, which suggested that Ori prevented Aβ-induced
synaptic loss. Additionally, Ori increased the expression of PSD95 and synaptophysin in Aβ-
treated primary cortical neurons. In agreement with the hypothesis that abnormal dendritic
morphology is involved in the process of synaptic dysfunction in transgenic mouse models of
AD[40–42], we found that Aβ negatively impacted dendritic morphology in AD mice. Mean-
while, Ori increased the overall dendritic length and number of branches and enhanced the
number of dendritic spines, which favored the improvement of synaptic function and cognitive
deficits.

In recent years, synaptosomes, which are isolated from synapses, have been widely used for
the study of AD synapses[43,44]. Indeed, both structural and functional studies of the synapse
are supported by synaptosome preparation because they can be stimulated to release neuro-
transmitters and supply material for protein studies and reflect synaptic function[45]. Studies
from post-mortem human brains show that Aβ and p-tau are accumulated in synaptosomes
[46,47]. Moreover, the levels of oxidative markers are significantly increased in the synapto-
somes from AD postmortem frontal cortices, which implicates the participation of oxidative
stress in synaptic loss[48]. Nicotinamide and 3-aminobenzamide exert neuroprotective effects
in Aβ-induced AD rats by improving mitochondrial function in synaptosomes[49]. Our cur-
rent study showed that Ori increased the expression of PSD-95 and synaptophysin in the syn-
aptosomes of AD mice. We also analyzed mitochondrial activity, which was an index of
synaptosomal functional integrity, and found Ori improved the mitochondrial activity in syn-
aptosomes from the brains of AD mice. This suggested that Ori exerted protective effects of
synaptosomes.
BDNF and its receptor TrkB are widely expressed in the brain, and the binding of BDNF to TrkB regulates the survival and differentiation of neurons and modulates long-term potentiation and plasticity\cite{50,51}. In addition, the BDNF/TrkB signaling pathway is essential for modulating learning and memory\cite{52}. Emerging evidence shows that abnormal BDNF/TrkB signaling is associated with the progression of AD and is involved in the production of Aβ, tau hyperphosphorylation and cognitive impairment\cite{53}. BDNF/TrkB signaling pathway has also been implicated in the morphogenesis, strength, activity and plasticity of synapses, which suggests its crucial roles during various phases of synaptic development\cite{54}. This study confirmed that Ori activated the BDNF/TrkB pathway and increased the expression of p-CREB in the

![Fig 6. Ori increases the expression of BDNF in the hippocampus of AD mice. (A) Immunostaining for BDNF in the hippocampus. (B) Quantitative analysis of the expression of BDNF normalized to the control group. n = 5 mice per group and the experiment was performed for three times. Data are presented as the means ± SEM. *P<0.05, **P<0.01 vs. control; #P<0.05, ##P<0.01 vs. Aβ1-42. Scale bar = 50 μm.](Fig6.png)

doi:10.1371/journal.pone.0151397.g006
hippocampus of Aβ-induced AD mice, which might contribute to the neuroprotective effects of Ori. In summary, our current study demonstrates that the administration of Ori attenuates the synaptic dysfunction and exerts significant neuroprotective effects in Aβ1–42-induced AD mice. In addition, the potential mechanism could be associated with the activation of the BDNF/TrkB/CREB signaling pathway. Therefore, Ori might be a potential drug that targets synapses for the treatment of AD.

**Author Contributions**

Conceived and designed the experiments: YX XLZ SLW. Performed the experiments: SLW LJY HY. Analyzed the data: CSL ZH. Contributed reagents/materials/analysis tools: HY LJY CSL ZH. Wrote the paper: SLW LJY XLZ.

**References**

1. 2015 Alzheimer's disease facts and figures. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2015; 11(3):332–84. PMID: 25984581.

2. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nature neuroscience. 2012; 15(3):349–57. doi: 10.1038/nn.3028 PMID: 22286176.

3. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harbor perspectives in medicine. 2012; 2(5):a006270. doi:10.1101/cshperspect.a006270 PMID: 22553493.

4. Bai B, Hales CM, Chen PC, Gozal Y, Dammer EB, Fritz JJ, et al. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(41):16562–7. doi:10.1073/pnas.1310249110 PMID: 24203061.

5. Guerreiro R, Bras J, Hardy J. SnapShot: genetics of Alzheimer's disease. Cell. 2013; 155(4):968–e1. doi:10.1016/j.cell.2013.10.037 PMID: 24209629.

6. Pozueta J, Lefort R, Shelanski ML. Synaptic changes in Alzheimer's disease and its models. Neuroscience. 2013; 251:51–65. doi:10.1016/j.neuroscience.2012.05.050 PMID: 22687952.
7. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiology of aging. 2006; 27(10):1372–84. doi: 10.1016/j.neurobiolaging.2005.09.012 PMID: 16289476.

8. McClean PL, Holscher C. Liaglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology. 2014; 76 Pt A:57–67. doi: 10.1016/j.neuropharm.2013.08.005 PMID: 23973293.

9. Wei L, Lv S, Huang Q, Wei J, Zhang S, Huang R, et al. Pratensein attenuates Abeta-induced cognitive deficits in rats: enhancement of synaptic plasticity and cholinergic function. Fitoterapia. 2015; 101:208–17. doi: 10.1016/j.fitote.2015.01.017 PMID: 25665942.

10. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature reviews Neuroscience. 2013; 14(6):401–16. doi: 10.1038/nrn3505 PMID: 23674053.

11. Francis BM, Kim J, Barakat ME, Fraenkl S, Yucel YH, Peng S, et al. Object recognition memory and BDNF expression are reduced in young TgCRND8 mice. Neurobiology of aging. 2012; 33(3):555–63. doi: 10.1016/j.neurobiolaging.2010.04.003 PMID: 20447730.

12. Ciaramella A, Salani F, Bizzoni F, Orfei MD, Langella R, Angelucci F, et al. The stimulation of dendritic cells by amyloid beta 1-42 reduces BDNF production in Alzheimer's disease patients. Brain, behavior, and immunity. 2013; 32:29–32. doi: 10.1016/j.bbi.2013.04.001 PMID: 23578995.

13. Leal G, Comprido D, Duarte CB. BDNF-induced local protein synthesis and synaptic plasticity. Neuropharmacology. 2014; 76 Pt C:639–56. doi: 10.1016/j.neuropharm.2013.04.005 PMID: 23602987.

14. Kim BK, Shin MS, Kim CJ, Baek SB, Ko YC, Kim YP. Treadmill exercise improves short-term memory by enhancing neurogenesis in amyloid beta-induced Alzheimer disease rats. Journal of exercise rehabilitation. 2014; 10(1):2–8. doi: 10.12965/jer.140086 PMID: 24678498.

15. Liu X, Ye K, Weinschenker D. Norepinephrine Protects against Amyloid-beta Toxicity via TrkB. Journal of Alzheimer's disease: JAD. 2015; 44(1):251–60. doi: 10.3233/JAD-141062 PMID: 25208620.

16. Middel S, Houeland G, Cavallucci V, Ammassari-Teule M, D’Ammelio M, Marie H. CREB is necessary for synaptic maintenance and learning-induced changes of the AMPA receptor GluA1 subunit. Hippocampus. 2013; 23(6):488–99. doi: 10.1002/hipo.22108 PMID: 23504989.

17. Rodriguez-Tornos FM, San Aniceto I, Cubelos B, Nieto M. Enrichment of conserved synaptic activity-responsive element in neuronal genes predicts a coordinated response of MEF2, CREB and SRF. PloS one. 2013; 8(1):e53848. doi: 10.1371/journal.pone.0053848 PMID: 23382855.

18. Kim J, Kwon JT, Kim HS, Han JH. CREB and neuronal selection for memory trace. Frontiers in neural circuits. 2013; 7:44. doi: 10.3389/fncir.2013.00044 PMID: 23519079.

19. Wang S, Yang H, Yu L, Jin J, Qian L, Zhao H, et al. Oridonin attenuates Abeta1-42-induced neuroinflammation and inhibits NF-kappaB pathway. PloS one. 2014; 9(8):e104745. doi: 10.1371/journal.pone.0104745 PMID: 25121593.

20. Zhu X, Ye L, Ge H, Chen L, Jiang N, Qian L, et al. Hopeahainol A attenuates memory deficits by targeting beta-amyloid in APP/PS1 transgenic mice. Aging cell. 2013; 12(1):85–92. doi: 10.1111/acel.12022 PMID: 23107435.

21. Zhao H, Wang SL, Qian L, Jin JL, Li H, Xu Y, et al. Diammonium glycyrrhizinate attenuates Abeta(1–42) -induced neuroinflammation and regulates MAPK and NF-kappaB pathways in vitro and in vivo. CNS neuroscience & pharmacology. 2013; 19(2):117–24. doi: 10.1111/cns.12043 PMID: 23279783.

22. Zhu X, Wang S, Yu L, Yang H, Tan R, Yin K, et al. TL-2 attenuates beta-amyloid induced neuronal apoptosis through the AKT/GSK-3beta/beta-catenin pathway. Int J Neuropsychopharmacol. 2014; 17 (9):1511–9. doi: 10.1017/S1461145714000315 PMID: 24641999.

23. Yu L, Wang S, Chen X, Yang H, Li X, Xu Y, et al. Orientin alleviates cognitive deficits and oxidative stress in Abeta1-42-induced mouse model of Alzheimer's disease. Life sciences. 2015; 121:104–9. doi: 10.1016/j.lfs.2014.11.021 PMID: 25497709.

24. Chen YT, Zang XF, Pan J, Zhu XL, Chen F, Chen ZB, et al. Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection. Clinical and experimental pharmacology & physiology. 2012; 39(9):751–8. doi: 10.1111/j.1440-1681.2012.05729.x PMID: 22651689.

25. Jin JL, Liou AK, Shi Y, Yin KL, Chen L, Li LL, et al. CART treatment improves memory and synaptic structure in APP/PS1 mice. Scientific reports. 2015; 5:10224. doi: 10.1038/srep10224 PMID: 25959573.

26. Palavicina JP, Wang H, Bianchi E, Xu S, Rao JS, Kang DE, et al. RanBP9 aggravates synaptic damage in the mouse brain and is inversely correlated to spinophilin levels in Alzheimer's brain synaptosomes. Cell death & disease. 2013; 4:e667. doi: 10.1038/cddis.2013.183 PMID: 23764848.

27. Shao CY, Mirra SS, Sait HB, Sacktor TC, Sigurdsson EM. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Abeta and tau pathology in transgenic mouse models of Alzheimer's disease. CNS neuroscience & therapeutics. 2013; 19(2):117–24. doi: 10.1002/ctn.2273 PMID: 23504989.
Alzheimer’s disease. Acta neuropathologica. 2011; 122(3):285–92. doi: 10.1007/s00401-011-0843-x PMID: 21630115.

28. Zeng Y, Zhang J, Zhu Y, Shen H, Lu J, Pan X, et al. Triptolide improves cognitive deficits by reducing amyloid beta and upregulating synapse-related proteins in a transgenic model of Alzheimer’s Disease. Journal of neurochemistry. 2015; 133(1):38–52. doi: 10.1111/jnc.13056 PMID: 25661995.

29. Yuki D, Sugiura Y, Zaima N, Akatsu H, Takei S, Yao I, et al. DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer’s disease. Scientific reports. 2014; 4:7130. doi: 10.1038/srep07130 PMID: 25410733.

30. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(39):16877–82. doi: 10.1073/pnas.0908706106 PMID: 19805389.

31. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005; 47(2):191–9. doi: 10.1016/j.neuron.2005.06.030 PMID: 16039562.

32. Mo JA, Lim JH, Sui AR, Lee M, Youn YC, Kim HJ. Cerebrospinal fluid beta-amyloid1–42 levels in the differential diagnosis of Alzheimer’s disease—systematic review and meta-analysis. PloS one. 2015; 10 (2):e0116802. doi: 10.1371/journal.pone.0116802 PMID: 25710596.

33. Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer’s disease. Journal of the neurological sciences. 1987; 78(2):151–64. PMID: 3572454.

34. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiology of aging. 1995; 16(3):285–98; discussion 98–304. PMID: 7566338.

35. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr., et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease. Neurology. 2001; 56(1):127–9. PMID: 11148253.

36. Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA. Cortical and subcortical patterns of synapto-physinlike immunoreactivity in Alzheimer’s disease. The American journal of pathology. 1991; 138 (1):235–46. PMID: 1899001.

37. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. Journal of neuropathology and experimental neurology. 1997; 56(8):933–44. PMID: 9258263.

38. Ferreira ST, Klein WL. The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiology of learning and memory. 2011; 96(4):529–43. doi: 10.1016/j.nlm.2011.08.003 PMID: 21914486.

39. Xu S, Liu G, Bao X, Wu J, Li S, Zheng B, et al. Rosiglitazone prevents amyloid-beta oligomer-induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number. Journal of Alzheimer’s disease: JAD. 2014; 39(2):239–49. doi: 10.4021/jad13041x PMID: 25341230.

40. Kirkwood CM, Cuchta J, Ikonomovic MD, Fish KN, Abrahamson EE, Murray PS, et al. Dendritic spine density, morphology, and fibrillar actin content surrounding amyloid-beta plaques in a mouse model of amyloid-beta deposition. Journal of neuropathology and experimental neurology. 2013; 72(8):791–800. doi: 10.1097/NEN.0b013e31829ecce9 PMID: 23960033.

41. Bettner T, Burgold S, Dorostkar MM, Fuhrmann M, Wegenast-Braun BM, Schmidt B, et al. Amyloid plaque formation precedes dendritic spine loss. Acta neuropathologica. 2012; 124(6):797–807. doi: 10.1007/s00401-012-1047-8 PMID: 22993126.

42. Price KA, Varghese M, Sowa A, Yuk F, Brautigam H, Ehrlich ME, et al. Altered synaptic structure in the hippocampus in a mouse model of Alzheimer’s disease with soluble amyloid-beta oligomers and no plaque pathology. Molecular neurodegeneration. 2014; 9:41. doi: 10.1186/1750-1326-9-41 PMID: 25312309.

43. Wilcox KC, Marunde MR, Das A, Velasco PT, Kuhns BD, Marty MT, et al. Nanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer’s-Associated Abeta Oligomers. PloS one. 2015; 10(4):e0125263. doi:10.1371/journal.pone.0125263 PMID: 25928376.

44. Sokolow S, Henkens KM, Bilousova T, Gonzalez B, Vinters HV, Miller CA, et al. Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer’s disease. Journal of neurochemistry. 2015; 133(3):368–79. doi: 10.1111/jnc.13091 PMID: 25393609.

45. Evans GJ. The synaptosome as a model system for studying synaptic physiology. Cold Spring Harbor protocols. 2015; 2015(5):421–4. doi: 10.1101/pdb.top074450 PMID: 25934942.
46. Sokolow S, Henkins KM, Williams IA, Vinters HV, Schmid I, Cole GM, et al. Isolation of synaptic terminals from Alzheimer’s disease cortex. Cytometry Part A: the journal of the International Society for Analytical Cytology. 2012; 81(3):248–54. doi:10.1002/cyto.a.22009 PMID: 22213704.

47. Postupna NO, Keene CD, Latimer C, Sherfield EE, Van Gelder RD, Ojemann JG, et al. Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer’s disease. Laboratory investigation; a journal of technical methods and pathology. 2014; 94(10):1161–72. doi: 10.1038/labinvest.2014.103 PMID: 25068655.

48. Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. Journal of neuropathology and experimental neurology. 2010; 69(2):155–67. doi: 10.1097/NEN.0b013e3181cb5af4 PMID: 20084018.

49. Bayrakdar ET, Armagan G, Uyanikgil Y, Kanit L, Koylu E, Yalcin A. Ex vivo protective effects of nicotinamide and 3-aminobenzamide on rat synaptosomes treated with Abeta(1–42). Cell biochemistry and function. 2014; 32(7):557–64. doi: 10.1002/cbf.3049 PMID: 25111857.

50. Chen K, Henry RA, Hughes SM, Connor B. Creating a neurogenic environment: the role of BDNF and FGF2. Molecular and cellular neurosciences. 2007; 36(1):108–20. doi: 10.1016/j.mcn.2007.06.004 PMID: 17656107.

51. Rivera C, Li H, Thomas-Crusells J, Lahtinen H, Viitanen T, Nanobashvili A, et al. BDNF-induced TrkB activation down-regulates the K+-Cl- cotransporter KCC2 and impairs neuronal Cl- extrusion. The Journal of cell biology. 2002; 159(5):747–52. doi: 10.1083/jcb.200209011 PMID: 12473684.

52. Yamada K, Nabeshima T. Brain-derived neurotrophic factor/TrkB signaling in memory processes. Journal of pharmacological sciences. 2003; 91(4):267–70. PMID: 12719654.

53. Zhang F, Kang Z, Li W, Xiao Z, Zhou X. Roles of brain-derived neurotrophic factor/tropomyosin-related kinase B (BDNF/TrkB) signalling in Alzheimer’s disease. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2012; 19(7):946–9. doi: 10.1016/j.jocn.2011.12.022 PMID: 22613489.

54. Yoshii A, Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Developmental neurobiology. 2010; 70(5):304–22. doi: 10.1002/dneu.20765 PMID: 20186705.